Skip to main content

Table 3 Association between mitotic count (left columns) and CCND1 (right columns) and clinico-pathological variables and other cell proliferation markers

From: Mitotic count can predict tamoxifen benefit in postmenopausal breast cancer patients while Ki67 score cannot

Variable levels Mitotic count per 2 mm2 CCND1 copy number ratiob
<  8 / 2 mm2 ≥ 8 / 2 mm2   <  0 >  0  
N (%) N (%) p valuea N (%) N (%) p valuea
Age <  65 133 (47) 133 (49) 0.72 101 (49) 129 (48) 0.72
  ≥ 65 150 (53) 141 (51)   104 (51) 142 (52)  
Nodal status negative 173 (61) 135 (49) 0.005 112 (55) 152 (56) 0.75
  positive 110 (39) 139 (51)   93 (45) 119 (44)  
T stage T1–2 262 (93) 235 (86) 0.01 180 (88) 245 (90) 0.36
  T3–4 21 (7) 39 (14)   25 (12) 26 (10)  
Grade grade 1–2 279 (99) 90 (33) < 0.001 142 (69) 171 (63) 0.16
  grade 3 4 (1) 184 (67)   63 (31) 100 (37)  
PgR negative 116 (42) 143 (52) 0.02 92 (46) 132 (50) 0.42
  positive 157 (58) 130 (48)   108 (54) 133 (50)  
Her2 negative 257 (93) 226 (84) < 0.001 180 (90) 233 (87) 0.46
  positive 3 (1) 38 (14)   13 (7) 22 (8)  
  missing 16 (6) 6 (2)   7 (4) 12 (4)  
Ki67 <  5% 104(53) 94 (42) 0.02 72 (54) 92 (46) 0.78
  ≥ 5% 92 (47) 130 (58)   88 (55) 106 (54)  
Cyclin D1 below median 106 (53) 100 (42) 0.02 76 (49) 105 (48) 0.85
  above median 93 (47) 140 (58)   80 (51) 115 (52)  
mitotic count <  8 per 2 mm2 283 (100) 0(0) na 116 (57) 126 (47) 0.03
  ≥ 8 per 2 mm2 0(0) 274 (100)   87 (43) 142 (53)  
CCND1 log 2 copy number ratiob <  0 116 (48) 87 (38) 0.03 205 (100) 0(0) na
>  0 126 (52) 142 (62)   0(0) 271 (100)  
  1. aChi-square test, analysis based on cases without missing values
  2. bprobe set 2